In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretio
BACKGROUND: The ability of abciximab to prevent fibrinogen binding to activated platelets indicates ...
In addition to inhibition of platelet aggregation, GPIIb-IIIa antagonists may reduce thrombotic even...
Abciximab is a new antiplatelet therapeutic in ischemic cardiovascular disease. The drug, chimeric F...
Inhibition of soluble fibrinogen binding to activated platelets represents the target of pharmacolog...
Background—Tests developed to monitor glycoprotein (GP) IIb/IIIa blockade do not properly reflect pl...
The internal pool of GPIIb/IIIa, which is expressed upon platelet activation, may be inaccessible to...
BACKGROUND: The best method for measuring the degree of platelet inhibition with glycoprotein (GP) I...
AbstractDespite the success of abciximab in preventing ischemic events after percutaneous coronary i...
The human glycoprotein (GP)IIb/IIIa belongs to a large family of cation-dependent adhesion molecules...
inhibition is assay dependent: A comparative study in patients undergoing percutaneous coronary inte...
Abciximab, ReoPro @ is the Fab fragment of the chimeric human-murine monoclonalantibody 7E3. Abcixim...
Background-—New antiplatelet agents that provide greater, more consistent inhibition of the platelet...
Aims: To compare three glycoprotein IIb/IIIa receptor antagonists (GPIs) in terms of platelet inhibi...
Soon after identification of the platelet membrane glycoprotein (GP) IIb/IIIa, it has become a targe...
As the glycoprotein GPIIb/IIIa receptor is the final common pathway in platelet aggregation, antagon...
BACKGROUND: The ability of abciximab to prevent fibrinogen binding to activated platelets indicates ...
In addition to inhibition of platelet aggregation, GPIIb-IIIa antagonists may reduce thrombotic even...
Abciximab is a new antiplatelet therapeutic in ischemic cardiovascular disease. The drug, chimeric F...
Inhibition of soluble fibrinogen binding to activated platelets represents the target of pharmacolog...
Background—Tests developed to monitor glycoprotein (GP) IIb/IIIa blockade do not properly reflect pl...
The internal pool of GPIIb/IIIa, which is expressed upon platelet activation, may be inaccessible to...
BACKGROUND: The best method for measuring the degree of platelet inhibition with glycoprotein (GP) I...
AbstractDespite the success of abciximab in preventing ischemic events after percutaneous coronary i...
The human glycoprotein (GP)IIb/IIIa belongs to a large family of cation-dependent adhesion molecules...
inhibition is assay dependent: A comparative study in patients undergoing percutaneous coronary inte...
Abciximab, ReoPro @ is the Fab fragment of the chimeric human-murine monoclonalantibody 7E3. Abcixim...
Background-—New antiplatelet agents that provide greater, more consistent inhibition of the platelet...
Aims: To compare three glycoprotein IIb/IIIa receptor antagonists (GPIs) in terms of platelet inhibi...
Soon after identification of the platelet membrane glycoprotein (GP) IIb/IIIa, it has become a targe...
As the glycoprotein GPIIb/IIIa receptor is the final common pathway in platelet aggregation, antagon...
BACKGROUND: The ability of abciximab to prevent fibrinogen binding to activated platelets indicates ...
In addition to inhibition of platelet aggregation, GPIIb-IIIa antagonists may reduce thrombotic even...
Abciximab is a new antiplatelet therapeutic in ischemic cardiovascular disease. The drug, chimeric F...
DOI
Add to ORKG